Table 1

Daptomycin MIC breakpoints established by the CLSI, FDA, and EUCAST

OrganismMIC breakpoint (μg/ml) established by a :
CLSI FDA EUCAST
SRSRSR
Staphylococcus ≤1 ≤1 ≤1>1
Enterococcus ≤4 ≤4 b
Beta-hemolytic Streptococcus ≤1 ≤1 ≤1>1
Viridans group Streptococcus, excluding S. pneumoniae ≤1
Corynebacterium ≤1
Lactobacillus ≤4
  • a S, susceptible; R, resistant; CLSI, Clinical and Laboratory Standards Institute; FDA, Food and Drug Administration; EUCAST, European Committee on Antimicrobial Susceptibility Testing.

  • b Due to the lack of clinical data, the FDA clinical breakpoint is approved for vancomycin-susceptible E. faecalis alone.